NCT05953610View on ClinicalTrials.gov

Endotypic Traits and Obstructive Sleep Apnea Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 7, 2024

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Obstructive Sleep Apnea
Interventions
DRUG

Acetazolamide 500 MG QHS

Acetazolamide

DRUG

Eszopiclone 3 mg QHS

Eszopiclone

Trial Locations (2)

90095

NOT_YET_RECRUITING

UCLA Westwood, Westwood, Los Angeles

90401

RECRUITING

UCLA Santa Monica Medical Center, Santa Monica

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of California, Los Angeles

OTHER